This study was a randomized clinical trial to evaluate the effect of  Punarnava Guggulu and Sanjivani Vati in the management of post chikunguya chronic inflammatory rheumatism. Total 32 patients were enrolled in present study. Selected patients were divided in two group on the basis of computer generated randomisation. In this study Punarnava Guggulu was given in dose 2 tablet (300 mg each) tds after food with warm water for 2 months and Sanjivni Vati was 2 tablet (125mg each) tds after food with warm water for 2 months,  Patients of both the group were also given two sitting of Sarvanga Vashpa Swedana, each sitting of 6 days in the morning with Dashmulakwatha during initial two week of  treatment.   Patients were allowed to use concomitant drugs during the course of trial.   Follow up will be carried out at 7 days interval for 1 month . Assessment was made on the basis of subjective criteria like chief complaints and associated complaints and objective criteria like ESR, CRP(Quantitative), VAS score, RAPID3 score and disability index. after applying statistical test highly significant improvement was found in both the group in subjective criteria. In objective criteria, statistically significant decrease was found in both the groups. by comparing two groups, statistically insignificant difference was found. Thus alernative hypothesis is rejected and null hypothesis i.e. "Punarnava Guggulu and Sanjivani Vati are effective in the management of post chikungunya chronic inflammatory rheumatism when given orally along with Sarvanga Vashpa Swedana". No any adverse drug reaction was found in both of the groups.